These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 6725216

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Studies of catecholamine metabolism in schizophrenia/psychosis--II.
    Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub SE.
    Neuropsychopharmacology; 1993 Feb; 8(2):111-6. PubMed ID: 8471122
    [Abstract] [Full Text] [Related]

  • 23. Recent life stressors and biological markers in newly admitted psychotic patients.
    Mazure CM, Quinlan DM, Bowers MB.
    Biol Psychiatry; 1997 Apr 15; 41(8):865-70. PubMed ID: 9099413
    [Abstract] [Full Text] [Related]

  • 24. Psychotic patients with increased plasma HVA and MHPG or increased HVA alone.
    Bowers MB.
    Biol Psychiatry; 1993 Oct 15; 34(8):584-6. PubMed ID: 8274591
    [No Abstract] [Full Text] [Related]

  • 25. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
    Swigar ME, Jatlow PI, Goicoechea N, Opsahl C, Bowers MB.
    Am J Psychiatry; 1984 Oct 15; 141(10):1281-3. PubMed ID: 6486269
    [Abstract] [Full Text] [Related]

  • 26. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ.
    Schizophr Res; 1993 Jun 15; 10(1):33-7. PubMed ID: 8369230
    [Abstract] [Full Text] [Related]

  • 27. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG.
    Psychopharmacol Bull; 1992 Jun 15; 28(1):101-7. PubMed ID: 1609034
    [Abstract] [Full Text] [Related]

  • 28. Risperidone in the treatment of psychotic depression.
    Goto M, Yoshimura R, Kakihara S, Shinkai K, Yamada Y, Kaji K, Ueda N, Nakamura J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun 15; 30(4):701-7. PubMed ID: 16580110
    [Abstract] [Full Text] [Related]

  • 29. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D.
    J Clin Psychiatry; 1984 Jan 15; 45(1):10-3. PubMed ID: 6363395
    [Abstract] [Full Text] [Related]

  • 30. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD, Hershey LA, Duffy JP, Abernethy DR, Greenblatt DJ.
    J Clin Psychopharmacol; 1984 Dec 15; 4(6):305-10. PubMed ID: 6511996
    [Abstract] [Full Text] [Related]

  • 31. Acute psychosis and plasma catecholamine metabolites.
    Bowers MB, Swigar ME.
    Arch Gen Psychiatry; 1987 Feb 15; 44(2):190. PubMed ID: 3813817
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Schizophrenia: gender, family risk, and plasma homovanillic acid.
    Dávila R, Zumárraga M, González-Torres MA, Andía I, Zamalloa MI, Basterreche E, Guimón J, Friedhoff AJ.
    Am J Med Genet; 1995 Apr 24; 60(2):154-6. PubMed ID: 7485251
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR, Müller-Spahn F, Rüther E, Scherer J.
    Pharmacopsychiatry; 1988 Sep 24; 21(5):226-31. PubMed ID: 3227054
    [Abstract] [Full Text] [Related]

  • 36. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H.
    Hum Psychopharmacol; 2005 Jun 24; 20(4):243-8. PubMed ID: 15830401
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul 24; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 40. Utility of neuroleptic blood levels in the treatment of acute psychosis.
    Zohar J, Shemesh Z, Belmaker RH.
    J Clin Psychiatry; 1986 Dec 24; 47(12):600-3. PubMed ID: 3782046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.